These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33491528)

  • 21. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome.
    Javed Z; Papageorgiou M; Deshmukh H; Kilpatrick ES; Mann V; Corless L; Abouda G; Rigby AS; Atkin SL; Sathyapalan T
    Nutrients; 2019 Jan; 11(1):. PubMed ID: 30658483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.
    Hadi A; Mohammadi H; Miraghajani M; Ghaedi E
    Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449
    [No Abstract]   [Full Text] [Related]  

  • 23. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    Vadarlis A; Antza C; Bakaloudi DR; Doundoulakis I; Kalopitas G; Samara M; Dardavessis T; Maris T; Chourdakis M
    J Gastroenterol Hepatol; 2021 Feb; 36(2):311-319. PubMed ID: 32810309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
    Askari F; Rashidkhani B; Hekmatdoost A
    Nutr Res; 2014 Feb; 34(2):143-8. PubMed ID: 24461315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial.
    Malaguarnera M; Gargante MP; Russo C; Antic T; Vacante M; Malaguarnera M; Avitabile T; Li Volti G; Galvano F
    Am J Gastroenterol; 2010 Jun; 105(6):1338-45. PubMed ID: 20068559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
    Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
    Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial.
    Ebrahimpour-Koujan S; Gargari BP; Mobasseri M; Valizadeh H; Asghari-Jafarabadi M
    Phytomedicine; 2018 May; 44():39-44. PubMed ID: 29895491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease.
    Zhang PW; Chen FX; Li D; Ling WH; Guo HH
    Medicine (Baltimore); 2015 May; 94(20):e758. PubMed ID: 25997043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease.
    Parker A; Kim Y
    Metab Syndr Relat Disord; 2019 Oct; 17(8):389-396. PubMed ID: 31305201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.
    Wahlang B; Falkner KC; Gregory B; Ansert D; Young D; Conklin DJ; Bhatnagar A; McClain CJ; Cave M
    J Nutr Biochem; 2013 Sep; 24(9):1587-95. PubMed ID: 23618531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents.
    Pacifico L; Bonci E; Andreoli G; Romaggioli S; Di Miscio R; Lombardo CV; Chiesa C
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):737-43. PubMed ID: 24656140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.
    Hu Y; Liu J; Dong X; Xu Y; Leng S; Wang G
    Med Sci Monit; 2016 Nov; 22():4146-4151. PubMed ID: 27803497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
    Loguercio C; Andreone P; Brisc C; Brisc MC; Bugianesi E; Chiaramonte M; Cursaro C; Danila M; de Sio I; Floreani A; Freni MA; Grieco A; Groppo M; Lazzari R; Lobello S; Lorefice E; Margotti M; Miele L; Milani S; Okolicsanyi L; Palasciano G; Portincasa P; Saltarelli P; Smedile A; Somalvico F; Spadaro A; Sporea I; Sorrentino P; Vecchione R; Tuccillo C; Del Vecchio Blanco C; Federico A
    Free Radic Biol Med; 2012 May; 52(9):1658-65. PubMed ID: 22343419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sesame oil and vitamin E co-administration may improve cardiometabolic risk factors in patients with metabolic syndrome: a randomized clinical trial.
    Farajbakhsh A; Mazloomi SM; Mazidi M; Rezaie P; Akbarzadeh M; Ahmad SP; Ferns GA; Ofori-Asenso R; Babajafari S
    Eur J Clin Nutr; 2019 Oct; 73(10):1403-1411. PubMed ID: 31089253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.